Search

Displaying results 8081 - 8090 of 8410 in total
  1. Drug

    Calanolide A

    go.drugbank.com/drugs/DB04886
    Investigational

    Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat suscepti...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 Inhibitors
  3. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. ...

    Categories: P-glycoprotein inhibitors
  4. Drug

    Bezisterim

    go.drugbank.com/drugs/DB05212
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    KOS-1584

    go.drugbank.com/drugs/DB05903
    Investigational

    KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-1584 is a second-generation compound with increased pote...

    Synonyms: (E)-9,10-Dehydroepothilone D, (E)-9,10-Didehydroepothilone DCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  6. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result, CT...

  7. Drug

    Garenoxacin

    go.drugbank.com/drugs/DB06160
    Experimental

    Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Elocalcitol

    go.drugbank.com/drugs/DB06194
    Experimental

    Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).

    Categories: Vitamin D and Analogues
  9. Drug

    Lestaurtinib

    go.drugbank.com/drugs/DB06469
    Investigational

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  10. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates